News >

Optimizing Immunotherapy in Lung Cancer

Angelica Welch
Published: Thursday, Mar 01, 2018

Claude Denham, MD
Claude Denham, MD
Immunotherapy continues to establish itself in the treatment of patients with non–small cell lung cancer (NSCLC), yet physicians continue to face challenges in later-line settings with resistance, hyperprogression, and optimal responders.

State of the Science Summit™ on Non–Small Cell Lung Cancer, Denham, a medical oncologist at Baylor Charles A. Sammons Cancer Center, discussed the use of immunotherapy beyond the first-line setting in NSCLC. In an interview during the event, he dove deeper into the challenges with immunotherapy in this disease, as well as the promise of combination therapy.

OncLive: Can you give an overview of your presentation?

Denham: My topic lays the groundwork for a lot of the others—it is the use of immunotherapy, largely anti–PD-1 therapy, for NSCLC. I reviewed the pivotal trials that have demonstrated that this is essentially the standard of care for most patients in the second-line setting for NSCLC, both adenocarcinoma and squamous cell carcinoma.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x